The Direct-to-Consumer Drug Boom Demands a New Data Playbook

Direct-to-consumer drug sales are moving from experiment to strategy. Major pharmaceutical companies are increasingly bypassing traditional pharmacy channels to sell prescription medications directly to patients, motivated by a straightforward promise: fewer intermediaries, better pricing transparency, and a more controlled patient experience.

But this is not just a channel shift. It is a shift in responsibility, and especially in data accountability.

When manufacturers go direct, they inherit the full burden of managing the patient relationship end-to-end. That includes identity management, consent tracking, communication preferences, fulfillment and logistics, adherence monitoring, support interactions, and ongoing engagement. Retail pharmacies and major retailers spent decades building the systems and operational muscle to do this at scale. Most pharmaceutical companies did not.

The economics are compelling, particularly for high-demand therapies and specialty medications that aren’t consistently covered by insurance. Cutting out intermediaries can reduce out-of-pocket costs and widen access. Federal efforts to lower prescription drug prices, including agreements with major manufacturers and the planned launch of “TrumpRx” in 2026, signal that the direct-to-patient model may expand even faster than expected. Several manufacturers have already launched direct programs, offering meaningful discounts and reporting growing volume through these channels.

The commercial momentum is real. The hidden challenge is whether the data infrastructure behind these programs can keep pace with the operational complexity that direct relationships entail.

The invisible infrastructure retail pharmacies already built

For decades, retail pharmacies did far more than dispense medications. They built the infrastructure that made modern patient engagement possible: persistent patient identity across channels, refill and adherence programs, household and caregiver relationships, prior authorization workflows, and payer coordination. They maintained detailed records of consent and communication preferences and executed reminders and outreach across email, SMS, apps, and call centers.

Much of that capability was invisible to manufacturers because the data largely stayed with the retailer. In the traditional model, information moved downstream: manufacturer to distributor to pharmacy. Pharma organizations optimized around product, prescriber, and wholesale relationships, investing in systems to manage SKUs, support sales reps, and track channel performance. They were built for a B2B world.

Direct-to-consumer reverses that logic. When the patient becomes the customer, the manufacturer must operate like a retailer, but under stricter regulatory and safety requirements.

Why legacy pharma data stacks break down in a DTC model

A direct-to-patient channel creates new, high-frequency questions that legacy data architectures weren’t designed to answer: Is this the same patient who contacted us last week through email and then called support yesterday? Have we honored their marketing opt-out across every downstream system? Do we have the right identity and address for fulfillment? Are we tracking adherence patterns well enough to identify risk and intervene appropriately?

Answering those questions requires a unified view of the patient across web interactions, mobile experiences, contact centers, e-commerce and payment systems, fulfillment history, and safety communications. It requires matching and merging records across systems that were never built to interoperate.

And the stakes in pharma are meaningfully higher than in traditional retail. A duplicate record at an e-commerce company creates annoyance. A duplicate patient record at a pharmaceutical manufacturer can lead to incorrect communications, privacy violations, regulatory penalties, or even unsafe outcomes.

At the same time, consumers increasingly expect retail-grade experiences: real-time updates, frictionless onboarding, personalized support, and consistency across channels. Pharma leaders are being asked to deliver that standard while navigating HIPAA, evolving state privacy laws, and FDA requirements for safety communications. The expectations are retail. The consequences are healthcare.

Retail-grade data, pharma-grade compliance

To succeed in direct-to-consumer, pharmaceutical companies need data capabilities that look more like modern retail, with controls that meet healthcare-grade compliance requirements. That means real-time identity resolution across channels, a complete audit trail for data changes, and granular consent management that distinguishes between marketing preferences and mandatory safety notifications. It also means governance strong enough to support privacy and regulatory needs without slowing down the business.

Building these capabilities internally can take years, with significant cost and execution risk. The practical alternative is adopting a unified data platform purpose-built to create a single, trusted view of the patient while integrating with existing CRM, digital, and fulfillment systems.

Closing the infrastructure gap

The direct-to-consumer shift is one of the most significant go-to-market transformations in modern pharma. The winning companies will treat data infrastructure as a strategic prerequisite rather than a back-office project.

For pharmaceutical leaders navigating this transition, Reltio’s new white paper, “The 10 Data Rules to Win in the Age of Intelligence,” offers a practical framework for building data strategies that support compliance, sustainable growth, and real-time operations. Download the guide to learn how industry-leading organizations are building trusted, unified data foundations for the next era of patient engagement.